|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
The manufacture of sterile pharmaceutical products is governed in the European Union by the requirements of EU Good Manufacturing Practice for Medicinal Products. The GMP guide gives very specific details on the environmental and microbial requirements for aseptic processing. However, little or no guidance is given on how to create and maintain the correct level of microbial contamination in the aseptic suite. This article focuses on two important issues - creating and maintaining a spore-free environment and preventing spore contamination that may result from the use of disinfectants.
Control of Bacterial Spores
One of the most difficult requirements in a life science cleanroom is the control of bacterial spores. They can enter the cleanroom on people and on components at a surprisingly high rate. Research has shown that 40 per cent of consumables as they are taken from stores are contaminated with bacterial spores (1). The rest of the study showed that if the transfer disinfection procedure employed comprised of spraying solely with alcohol, only 27.6 per cent of the spores would be removed. The results of the different methods tested are shown in Table 1. Annexe 1 of GMP states that 'transfer of materials into and out of the unit is one of the greatest potential sources of contamination' (2).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Vetter Drives its Sustainability Campaign Forward
Repeat participation in Baden Wuerttemberg’s Sustainability Days
Greater inclusion of employees due to involvement in various initiatives
Awards pay tribute to a comprehensive sustainability strategy
More info >> |
|
 |
White Papers |
 |
|
Device Develop for Combo Products
Phillips-Medisize
Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >> |
|
|
